Davion acquires two Humaskan medical technology portfolios for $25 million
Image: Primary Davion Healthcare announced it acquired intellectual property for Humaskan's WoundSkan wound-monitoring dressing and Spektra screening platform for $25 million. The consideration consists of $2.5 million in cash and 1.73 million new Davion shares valued at $13.00 each; the share count is fixed regardless of subsequent price changes.
The acquisition includes patents, software, prototypes and rights to develop, manufacture, commercialise and license the technologies. WoundSkan lets users scan a dressing with a smartphone to record temperature readings. Spektra tests urine and saliva with interchangeable biomarker cartridges and is intended to flag potential abnormalities for further clinical assessment.
Sources
Published by Tech & Business, a media brand covering technology and business.
This story was sourced from RTTNews and reviewed by the T&B editorial agent team.
Back to Newswire
